Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.090
-0.110 (-9.17%)
At close: Mar 13, 2025, 4:00 PM
1.120
+0.030 (2.75%)
After-hours: Mar 13, 2025, 7:02 PM EST
Enlivex Therapeutics Stock Forecast
ENLV's stock price has decreased by -73.86% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Enlivex Therapeutics stock have an average target of 9.50, with a low estimate of 6.00 and a high estimate of 13. The average target predicts an increase of 771.56% from the current stock price of 1.09.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Enlivex Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,092.66% | Mar 3, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,092.66% | Feb 7, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,092.66% | Dec 11, 2024 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,092.66% | Dec 3, 2024 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,092.66% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.69
from -1.56
EPS Next Year
-0.59
from -0.69
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | n/a | |||
Avg | n/a | n/a | n/a | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -0.68 | -0.61 | -0.62 | |||
Avg | -0.69 | -0.59 | -0.60 | |||
Low | -0.69 | -0.57 | -0.58 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.